Estimating the benefits of adjuvant systemic therapy for women with early breast cancer

Author:

Grogan M1,Tabar L2,Chua B1,Chen H-H3,Boyages J1

Affiliation:

1. New South Wales Breast Cancer Institute, Westmead Hospital, University of Sydney, Westmead, New South Wales, Australia

2. Department of Mammography, Central Hospital, Falun, Sweden

3. Department of Epidemiology, College of Public Health, Taiwan University, Taipei, Taiwan

Abstract

Abstract Background Prognostic factors are commonly used to help identify women with node-negative breast cancer at high risk of recurrence. Although many are available, knowing which risk factor or combination of factors to use to estimate prognosis for an individual woman is often difficult. This study documented the baseline prognoses for a group of women with node-negative breast cancers, and estimated the potential benefits of adjuvant systemic therapy. Methods Ten-year, actuarial, cause-specific survival based on tumour size and histological grade using data from the Swedish Two-County Trial of mammographic screening was calculated for 1200 women with node-negative cancers of less than 30 mm diameter. The benefits of adjuvant systemic therapy for these women were then estimated using the published odds reductions in death from adjuvant systemic therapy from the Early Breast Cancer Trialists' Collaborative Group overview. Results The absolute 10-year survival benefits for subgroups of women based on tumour size and histological grade were estimated for women aged under 50 years by the addition of chemotherapy, and over 50 years by the addition of tamoxifen and/or chemotherapy. Conclusion Decisions about adjuvant systemic therapy in women with node-negative breast cancer need to be individualized, taking into account treatment efficacy and toxicity. The quantitative methods presented in this paper facilitate such decisions.

Publisher

Oxford University Press (OUP)

Subject

Surgery

Reference14 articles.

1. Polychemotherapy for early breast cancer: an overview of the randomised trials;Early Breast Cancer Trialists' Collaborative Group;Lancet,1998

2. Tamoxifen for early breast cancer: an overview of the randomised trials;Early Breast Cancer Trialists' Collaborative Group;Lancet,1998

3. Impact of a personal computer based tool for providing individualized estimates of outcomes for patients with early breast cancer;Siminoff;Proceedings of the American Society of Clinical Oncology,1998

4. A practical view of prognostic factors for staging, adjuvant treatment planning, and as baseline studies for possible future therapy;Ravdin;Hematol Oncol Clin North Am,1994

5. New Swedish breast cancer detection results for women aged 40–49;Tabar;Cancer,1993

Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3